Background: Left ventricular mass offers prognostic information for assessing cardiovasculardisease risk.
2
Background: Education is inversely associated with cardiovasculardisease incidence in developed countries.
3
Context: The risk factors for cardiovasculardisease and erectile dysfunction are similar.
4
Objective: Microalbuminuria is associated with increased risk of cardiovasculardisease and mortality.
5
Background: Moderate alcohol consumers have lower rates of cardiovasculardisease than abstainers.
1
Subclinical CVdisease was associated with age and dyslipidemia but not with other risk factors.
2
These effects seem particularly important for reducing risk of CVdisease in patients with the metabolic syndrome.
3
This study provides preliminary data for developing an integrated model of multidisciplinary care for the management of CVdisease.
4
Increasing the understanding of the pathogenesis of various CVdiseases may provide novel therapeutic targets to improve their prevention and treatment.
5
The metabolic syndrome (MS) represents a cluster of cardiovascular (CV ) risk factors associated to CVdisease and type 2 diabetes.
1
Leading causes of death were due to nutrition and metabolic diseases followed by diseasesofthecirculatorysystem.
2
Diseasesofthecirculatorysystem (mainly acute myocardial infarction) and fractures were the most common reasons for hospitalisation of European patients abroad.
1
Objective: Cigarette smoking is an important modifiable risk factor for cardiovasculardiseases.
2
The risk for developing cardiovasculardiseases was not different between the groups.
3
Background and purpose: PDGF-BB is an angiogenic factor involved in cardiovasculardiseases.
4
Conclusion: Telomere shortening has been reported in several metabolic and cardiovasculardiseases.
5
The Company is principally focused on developing genetically-targeted therapies for cardiovasculardiseases.
1
This risk is the result of traditional and nontraditional CVD risk factors.
2
Predicted and observed CVD-free survival showed good agreement in all validation sets.
3
Heightened risk of CVD is often attributable to treatment with anthracycline chemotherapy.
4
Participants: Participants with self-reported history of established diagnosis of CVD were excluded.
5
Age-associated changes of such cells may enhance the risk of developing CVD.
6
Conclusion: The data suggest differences in CVD symptoms and clusters by sex.
7
The relationship of dietary caloric intake and CVD risk is less certain.
8
Approximately half of the elderly adults had moderate or high CVD risk.
9
Predictors of rapid kidney decline included prevalent and subclinical measures of CVD.
10
No associations between MAZ-Ab OD and conventional CVD risk factors were identified.
11
Identification of novel therapeutic targets and biomarkers for CVDs is urgently needed.
12
The CVD risk factors were collected at baseline and at 6-month follow-up.
13
To date, no lifetime risk estimates of total CVD have been reported.
14
Nanocomposite films were deposited from the colloid concurrently with conventional CVD precursors.
15
Total CVD included CAD or history of physician-diagnosed stroke or heart failure.
16
CVD risk factors are markedly elevated in HIV-infected patients with fat redistribution.